Breaking News
September 18, 2018 - Protect your heart and health during ‘dog days’ of summer
September 18, 2018 - Faculty receive awards for promise in biomedical research, clinical care | News Center
September 18, 2018 - Digital games for CVD-related self-management improve exercise capacity and energy expenditure
September 18, 2018 - Adding PET scans to CT imaging can change treatment for women with cervical cancer
September 18, 2018 - Zika virus vaccine shows promise for treatment of fatal glioblastoma
September 18, 2018 - Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of Yupelri (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
September 18, 2018 - INSiGHT identifies unique retinal regulatory genes
September 18, 2018 - Diversity, science leadership grants awarded to student-faculty pairs | News Center
September 18, 2018 - Many parents blame electronics for sleep problems among teens
September 18, 2018 - Researchers study neuronal activity in brain that prevents individuals from doing physical activity
September 18, 2018 - Purifying Proteins from Mammalian Cell Culture
September 18, 2018 - Researchers map 3D structure of toxic proteins used by Pseudomonas aeruginosa to trigger infection
September 18, 2018 - Outcome of ACL reconstruction related to the way you move post-surgery
September 18, 2018 - Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer
September 18, 2018 - Ardelyx Submits New Drug Application for Tenapanor for IBS-C
September 18, 2018 - Sociodemographic disparities in eyeglass use among elderly
September 18, 2018 - New Drug Shows Promise for Progressive Form of MS
September 18, 2018 - Babies exposed to higher levels of organochlorine compounds in womb may have worse lung function
September 18, 2018 - Women exposed to trauma in their lives gave birth to underweight male infants
September 18, 2018 - Probiotic supplementation may reduce use of antibiotics, scientific analysis shows
September 18, 2018 - Resveratrol decreases pain severity and levels of inflammatory biomarkers in osteoarthritis patients
September 18, 2018 - Research shows pollution is reaching the placenta
September 18, 2018 - KAIST researchers develop heart-targeting drug delivery technology using tannin acid
September 18, 2018 - Muscle relaxants used during general anesthesia can increase risk of pulmonary complications
September 18, 2018 - Silicone breast implants may increase risk of rare adverse outcomes in women
September 18, 2018 - Pediatricians Have a Role in Encouraging Play Among Children
September 18, 2018 - California’s Medicaid program hits ‘print’ when the feds need info
September 18, 2018 - Genes, environment and schizophrenia—new study finds the placenta is the missing link
September 18, 2018 - Boehringer Ingelheim announces study results of COPD patients treated with Spiolto Respimat
September 18, 2018 - PAREXEL launches Patient Innovation Center to improve drug development process
September 18, 2018 - Children’s National and NIAID launch pediatric clinical research partnership
September 18, 2018 - Researchers may be overlooking complexities in social relations of primates
September 18, 2018 - Key signaling molecule that helps stem cells make healthy bone declines as we age
September 18, 2018 - More women veterans with chronic pain use CIH therapies than men
September 18, 2018 - As Earth Warms, Heat-Related Deaths Will Multiply
September 18, 2018 - Labetalol use up for patients with preeclampsia and asthma
September 18, 2018 - MoreGrasp project shows significant results in field of thought-controlled grasp neuroprosthetics
September 18, 2018 - Drumming can benefit school children with autism
September 18, 2018 - Busyness can help people to make virtuous choices, research shows
September 18, 2018 - Two-minute bursts of in-class exercise breaks do not disrupt learning and teaching
September 18, 2018 - New online tools aid surgeons and specialists who care for older people
September 18, 2018 - Researchers use CRISPR to identify gene that helps cells resist flavivirus infection
September 18, 2018 - Brain’s support cells may play a central role in repetitive behaviors related to OCD
September 18, 2018 - Scientists discover novel mechanism by which synthesized proteins reach target compartment in cell
September 18, 2018 - Easy and rapid test for viral infections can cut antibiotic use, hospitalizations
September 18, 2018 - Gunshot victims more likely to require blood transfusions and die than other trauma patients
September 18, 2018 - Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
September 18, 2018 - Older adults fitted with cochlear implants exhibit poor brain function
September 18, 2018 - Inexpensive testing spurs cancer patients’ relatives to assess own disease risk | News Center
September 18, 2018 - Aging may have originated at the very beginning of life, says study
September 18, 2018 - New research on sperm quality updates advice for couples trying to conceive
September 18, 2018 - Paracetamol use in infancy may increase risk of developing asthma by the age of 18
September 18, 2018 - Promising gene therapy for ‘day blind’ sheep now safe for clinical trials in human patients
September 18, 2018 - New research shows evidence of soot from polluted air in placentas
September 17, 2018 - Expanding primary care buprenorphine treatment could curb opioid overdose crisis
September 17, 2018 - A look inside the child detention centers near the U.S. border
September 17, 2018 - New issue considers role of coronary angiography after cardiac arrest
September 17, 2018 - Scientists explore whether seafood could be the source of next anti-cancer drug
September 17, 2018 - Epidural stimulation aids in recovery of individuals with spinal cord injury
September 17, 2018 - ATS publishes new guideline on role of weight management in sleep apnea treatment
September 17, 2018 - Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis
September 17, 2018 - Risks Posed by Spreading Oil and Gas Wastewater on Roads
September 17, 2018 - How to choose a nursing home: MedlinePlus Medical Encyclopedia
September 17, 2018 - Death from touching fentanyl? A myth, says Trump administration training video
September 17, 2018 - Physician or physician-scientist — a new curriculum at the School of Medicine trains both
September 17, 2018 - Why Genetic Mutations Cause Disease in Some People but Not Others
September 17, 2018 - EU-funded project makes recommendations to protect rights of intersex people
September 17, 2018 - Discovery of unusual biosynthetic pathways could aid in the search for new natural products
September 17, 2018 - FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults
September 17, 2018 - People battling substance use disorders may benefit from meth-relapse prevention compound
September 17, 2018 - Inhaled steroid use linked to greater risk of NTM lung infections
September 17, 2018 - KKH develops new test to enable faster diagnosis of critically ill children with rare diseases
September 17, 2018 - How to Reassure Kids When Florence Strikes
September 17, 2018 - Scientists develop new technique to heal large ulcers by reprogramming wound cells into skin cells
September 17, 2018 - How researchers are working to render disease obsolete
September 17, 2018 - Study confirms link between use of muscle relaxants and respiratory complications
September 17, 2018 - Machine learning program could distinguish between two lung cancer types
September 17, 2018 - Ensysce receives award from NIDA to undertake development of opioid overdose protection platform
September 17, 2018 - Women with undiagnosed STIs may be at greater risk of negative premenstrual symptoms
September 17, 2018 - New discovery could improve diagnosis and treatment of lupus in black Africans
FDA Accepts Remoxy NDA For Review

FDA Accepts Remoxy NDA For Review

image_pdfDownload PDFimage_print

Treatment for Pain

FDA Accepts Remoxy NDA For Review

AUSTIN, Texas, March 01, 2018 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S. Food and Drug Administration (FDA) has determined that a New Drug Application (NDA) for Remoxy ER, the Company’s lead drug candidate, is sufficiently complete to permit a substantive review.

The FDA has set an action date of August 7, 2018 under the Prescription Drug User Fee Act (PDUFA). The Company believes the FDA will hold an open advisory committee meeting to discuss Remoxy ER, although a date has not yet been determined.

“The acceptance of the Remoxy NDA marks another important milestone for Pain Therapeutics,” said Remi Barbier, Chairman, President and Chief Executive Officer of Pain Therapeutics. “We are grateful to everyone who has contributed to the development of Remoxy ER over the years. We now look forward to working closely with the FDA during the regulatory review process.”

Remoxy ER is an abuse-deterrent, extended-release, capsule formulation of oxycodone (CII), a prescription drug for severe pain. Remoxy ER has a thick, sticky, high-viscosity capsule formulation designed to deter unapproved routes of drug administration, such as injection, snorting or smoking. Pain Therapeutics developed REMOXY ER to make oxycodone difficult to abuse yet provide 12 hours of steady pain relief when used appropriately by patients with pain.

Pain Therapeutics filed the Remoxy NDA through the 505(b)(2) regulatory pathway.

About Opioid Abuse

Opioid drugs such as oxycodone are an important treatment option for patients with severe chronic pain. However, oxycodone abuse and diversion remain serious, persistent problems. Opioid overdose deaths exceeded 64,000 in 2016, according to the Center for Disease Control (CDC). For over a decade, Pain Therapeutics has pioneered Abuse-Deterrent Formulations (ADFs) to help in the fight against prescription drug abuse. ADFs attempt to raise the bar on prescription drug abuse by making it more difficult, longer or aversive to tamper with long-acting opioid formulations, recognizing that no drug can be made abuse-proof.

About Pain Therapeutics, Inc.

We develop proprietary drugs that offer significant improvements to patients and physicians. Our expertise consists of developing new drugs and guiding these through various regulatory and development pathways in preparation for their eventual commercialization. We generally focus our drug development efforts around disorders of the nervous system. The FDA has not yet established the safety or efficacy of our drug candidates.

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the abuse deterrent properties of REMOXY ER; the timing of the regulatory review by the FDA of the REMOXY NDA; and the potential approval by the FDA of REMOXY ER. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to development and testing of our drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates; the uncertainty of patent protection for our intellectual property or trade secrets; unanticipated additional research and development, litigation and other costs; and the potential for abuse-deterrent pain medications or other competing products to be developed by competitors and potential competitors or others. For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.

Source: Pain Therapeutics, Inc.

Posted: March 2018

Related Articles

  • Pain Therapeutics Resubmits New Drug Application for Remoxy ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain – February 13, 2018
  • Pain Therapeutics Receives Complete Response Letter for Remoxy ER – September 26, 2016
  • FDA Accepts Remoxy NDA for Review – April 12, 2016
  • Pain Therapeutics Resubmits Remoxy New Drug Application to the U.S. Food and Drug Administration – March 29, 2016
  • Pfizer to Discontinue Agreement on Remoxy (oxycodone) Extended-Release Capsules CII – October 27, 2014
  • FDA Complete Response Letter Received for Remoxy – June 24, 2011
  • Remoxy New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 – January 27, 2011
  • King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for Remoxy – December 27, 2010
  • Pain Therapeutics Receives Complete Response Letter From FDA for Remoxy – December 11, 2008
  • Pain Therapeutics and King Pharmaceuticals Announce Submission of
    New Drug Application for Remoxy
    – June 10, 2008

Remoxy ER (oxycodone) FDA Approval History

Tagged with:

About author

Related Articles